Recce Pharmaceuticals signs MoU with Indonesian partner to progress anti-infectives

Latest News

Recce Pharmaceuticals (ASX:RCE) has signed a Memorandum of Understanding (MoU) with Indonesian organisation PT Etana Biotechnologies (Etana) to accelerate the development of the Australian company's anti-infective portfolio.

The MoU has been supported by the Australian and Indonesian Governments. Australian ambassador to Indonesia, Penny Williams PSM, and the Indonesian health minister Budi Sadikin publicly endorsed the initiative.

Minister Sadikin said, “The global health challenge of antimicrobial resistance is a pressing issue on the world stage. Indonesia welcomes collaborative initiatives and supports efforts to combat antimicrobial resistance, including the development of innovative therapeutics for infectious diseases.”

The Indonesian Government has highlighted the need for new therapeutics to address antimicrobial resistance in the country. More than 10 per cent of the country's adult population (19.5 million) have diabetes, a disease that can lead to higher probabilities of infections. A recent study showed that 15 per cent of sepsis patients in Indonesian hospitals had suffered from Diabetes.

Recce Pharmaceuticals CEO James Graham said, “This Bilateral Collaboration between Recce and Etana, signifies the Australian and Indonesian Governments’ shared commitment to advancing public health, fostering innovation, and addressing the global challenge of AMR in the Asia Pacific region. By combining our expertise and resources, we can make significant strides towards a healthier and more resilient future for both our nations and the global community.”